Annexon Inc (ANNX) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Annexon Inc   (NASDAQ: ANNX)

Annexon Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Annexon Inc in the second quarter 2026?
Annexon Inc recorded a cumulative net loss of $-203 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -106.15%.

Within the Major Pharmaceutical Preparations industry 259 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 3456 to 3553.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change -6.51 % -16.1 % -27.79 % -51.31 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -203 -198 -209 -209 -189
Return On Equity (TTM) -106.15 % -102.15 % -102.24 % -93.11 % -70.74 %
ANNX's Total Ranking # 3553 # 3456 # 3104 # 3024 # 2976
Equity (TTM) in Millions 186 205 212 161 199
Seq. Equity Change -9.03 % -3.36 % 31.1 % -18.88 % -18.36 %
Seq. Net Income Change - - - - -

Back to ANNX Management Effectiveness >> ANNX's 5 Years Annual ROE >> Compare ANNX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 260
Sector # 565
Overall # 3553

Return On Equity Statistics
High Average Low
-30.86 %
-62.94 %
-106.15 %
(Jun 30 2021)   (Jun 30 2026)



  News about Annexon Inc Return on Equity ROE

Annexon Inc. Fortifies Team with Inducement Grants Amid Record Losses: A Strategic Move for Biopharma Growth,

Overview of Inducement GrantsOn March 17, 2025, Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on developing innovative therapies for classical complement-mediated neuroinflammatory diseases, announced the approval of an inducement equity grant to a new non-executive employee. This move was made under the terms of the company’s 2022 Employment Inducement Award Plan, following compliance with Nasdaq Listing Rule 5635(c)(4). The grant, approved on March 12, reflects Annexon’s continuing effort to attract skilled professionals as it navigates both clinical development and market challenges.Financial Context and Performance MetricsDespite these strategic hiring initiatives, Annexon s financial landscape illustrates ongoing challenges. The company reported a cumulative net loss of $138 million for the 12 months ending in the fourth quarter of 2024, resulting in a negative return on equity (ROE) of -44.29%. This figure positions Annexon significantly below industry competitors, with 88 other companies within the Major Pharmaceutical Preparations sector boasting higher ROE metrics. Although this data points to unfavorable financial conditions, it’s worth noting that the company’s ranking has improved, moving from an overall ROE rank of 2879 in the third quarter of 2024 to 2066 in the most recent quarter.



ANNX Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 212 293 251 231 232
Y / Y Equity Change -27.79 % 16.98 % 8.37 % -0.31 % -32.64 %
Net Income in Millions -209 -138 -134 -142 -130
Y / Y Net Income Change - - - - -
Return On Equity -98.53 % -47.15 % -53.58 % -61.4 % -56.2 %

Back to ANNX Management Effectiveness >> ANNX's 5 Years Annual ROE >> Compare ANNX ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ANNX's' Return on Equity at Yahoo Finance
ANNX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ANNX's Competitors
Subscribers only: Roe for Annexon Inc 's Suppliers
Subscribers only: Return On Equity for ANNX's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE

Date modified: 2026-09-04T10:00:26+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.